Changyang Gong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Changyang Gong has a total of 299 co-authors. Here are the top co-authors by number of shared publications:
Qinjie Wu
52 shared publicationsTao He
36 shared publicationsNing Wang
Department of Biotherapy Cancer Center and State Key Laboratory of Biotherapy West China Hospital Sichuan University Chengdu P. R. China
29 shared publications- Qinjie Wu
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
27 shared publications Xinchao Li
Department of Biotherapy Cancer Center and State Key Laboratory of Biotherapy West China Hospital Sichuan University Chengdu P. R. China
24 shared publicationsXi Yang
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China
23 shared publications
Latest Publications
- 6 October 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (41) , 27559-27640
Nano Delivery Systems for In Vivo CRISPR/Cas-Based Gene Therapy: From Vectors to Clinical Outcomes
As a powerful gene-editing tool, the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) system features simple construction, precise targeting, and higher editing efficiency, bringing prospects of radical cures for numerous critical illnesses at the genomic level. To date, ex vivo CRISPR/Cas-based gene therapies represented by Casgevy have achieved significant clinical advances. Nevertheless, cumbersome operational workflows and prohibitive treatment costs severely hinder their widespread clinical accessibility. In contrast, in vivo CRISPR/Cas-based gene therapies stand out with convenient administration procedures and reduced overall costs, endowing them with enormous translational potential. Although it holds great promise, the clinical translation of in vivo CRISPR/Cas-based gene therapies remains hampered by a number of factors. Among those multiple obstacles restricting the clinical translation of in vivo CRISPR/Cas-based gene therapies, delivery systems constitute the core bottleneck dominating in vivo editing efficiency and therapeutic potency. Centered on delivery platforms for in vivo CRISPR/Cas-based gene therapies, this review systematically summarizes prevailing in vivo CRISPR/Cas nano delivery systems, recapitulates relevant preclinical and clinical outcomes, discusses translational hurdles, and prospects the evolution of next-generation delivery systems, aiming to facilitate further development of in vivo CRISPR/Cas-based gene therapies.
- 6 October 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (41) , 27559-27640
Nano Delivery Systems for In Vivo CRISPR/Cas-Based Gene Therapy: From Vectors to Clinical Outcomes
As a powerful gene-editing tool, the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) system features simple construction, precise targeting, and higher editing efficiency, bringing prospects of radical cures for numerous critical illnesses at the genomic level. To date, ex vivo CRISPR/Cas-based gene therapies represented by Casgevy have achieved significant clinical advances. Nevertheless, cumbersome operational workflows and prohibitive treatment costs severely hinder their widespread clinical accessibility. In contrast, in vivo CRISPR/Cas-based gene therapies stand out with convenient administration procedures and reduced overall costs, endowing them with enormous translational potential. Although it holds great promise, the clinical translation of in vivo CRISPR/Cas-based gene therapies remains hampered by a number of factors. Among those multiple obstacles restricting the clinical translation of in vivo CRISPR/Cas-based gene therapies, delivery systems constitute the core bottleneck dominating in vivo editing efficiency and therapeutic potency. Centered on delivery platforms for in vivo CRISPR/Cas-based gene therapies, this review systematically summarizes prevailing in vivo CRISPR/Cas nano delivery systems, recapitulates relevant preclinical and clinical outcomes, discusses translational hurdles, and prospects the evolution of next-generation delivery systems, aiming to facilitate further development of in vivo CRISPR/Cas-based gene therapies.
- Open Access
- 20 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Metalloimmunological hydrogel-based cancer vaccine potentiates postoperative tumor immunotherapy
Adjuvant immune checkpoint inhibitor (AICI) therapy is limited by inadequate durable immunological memory against tumor recurrence and metastasis. Herein, we present a metalloimmunological hydrogel-based and innate immunity-focused cancer vaccine (IT-Vax) that synergizes innate-adaptive crosstalk to potentiate AICI efficacy. Through systematic screening of 9 polysaccharide hydrogels with dual crosslinking (metal coordination/Schiff base), manganese-incorporated formulations demonstrate superior dendritic cell (DC) activation capacity through orchestrating innate immune pathways. The optimized IT-Vax, incorporating with a ROCK inhibitor and mitoxantrone-treated tumor cells functionally achieves five-pronged DC modulations: enhanced lymphatic migration, antigen presentation, costimulation, and priming of effector and memory T cells. Correspondingly, this multi-faceted activation translates in vivo into a marked accumulation of key DC subsets, including cDC1s and migratory DCs. Consequently, in therapeutic models, IT-Vax culminates in a robust cellular immune response, as attested by a 3.6-fold tumor growth suppression. Notably, in orthotopic breast cancer models, one-dose personalized IT-Vax combined with AICI therapy reduces postoperative metastasis by around 60% and extends median survival from 37 to over 100 days. This study establishes a personalized vaccine platform that mechanistically bridges innate immunostimulation with sustained adaptive memory, providing a strategy with translational potential to overcome the limitations of postoperative immunotherapy.
- 20 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessMetalloimmunological hydrogel-based cancer vaccine potentiates postoperative tumor immunotherapy
Adjuvant immune checkpoint inhibitor (AICI) therapy is limited by inadequate durable immunological memory against tumor recurrence and metastasis. Herein, we present a metalloimmunological hydrogel-based and innate immunity-focused cancer vaccine (IT-Vax) that synergizes innate-adaptive crosstalk to potentiate AICI efficacy. Through systematic screening of 9 polysaccharide hydrogels with dual crosslinking (metal coordination/Schiff base), manganese-incorporated formulations demonstrate superior dendritic cell (DC) activation capacity through orchestrating innate immune pathways. The optimized IT-Vax, incorporating with a ROCK inhibitor and mitoxantrone-treated tumor cells functionally achieves five-pronged DC modulations: enhanced lymphatic migration, antigen presentation, costimulation, and priming of effector and memory T cells. Correspondingly, this multi-faceted activation translates in vivo into a marked accumulation of key DC subsets, including cDC1s and migratory DCs. Consequently, in therapeutic models, IT-Vax culminates in a robust cellular immune response, as attested by a 3.6-fold tumor growth suppression. Notably, in orthotopic breast cancer models, one-dose personalized IT-Vax combined with AICI therapy reduces postoperative metastasis by around 60% and extends median survival from 37 to over 100 days. This study establishes a personalized vaccine platform that mechanistically bridges innate immunostimulation with sustained adaptive memory, providing a strategy with translational potential to overcome the limitations of postoperative immunotherapy.
- Open Access
- 1 August 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 62, 263-281
Chronic inflammation-responsive hydrogel restores myeloid-T cell crosstalk to reinvigorate antitumor immunity against metastatic colorectal cancer
Chronic inflammation in intermediate/advanced tumors drives burdensome protumor immune cell communication, thereby weakening immunotherapy. Conventional anti-inflammatory therapies focus on alleviating chronic inflammation whereas ignore dysfunction and scarcity of myeloid and T cells, which hinder their intercellular communication restoration. To address the dilemma, an inflammatory condition-triggered protumor inflammation-immunosurveillance shift hydrogel (TRANS) is developed to initiate adaptive immune responses mediated by intercellular communication. Triggered by inflammatory conditions, TRANS releases celecoxib (CXB) to inhibit the COX-2/PGE2 pathway, thereby reprogramming tumor-associated macrophages and mitigating protumor inflammation. Furthermore, TRANS incorporates FMS-like tyrosine kinase 3 ligands (Flt-3L) and 4-1BB agonists (α-CD137) to respectively recruit type 1 conventional DC (cDC1) and revitalize tumor-infiltrating T cells, to rejuvenate immunosurveillance. TRANS inhibits 87.50% and 88.74% of primary and secondary colorectal tumors, generates antitumor immune memory to resist tumor rechallenge, and significantly reduces lung and liver metastases. Rechallenge model shows TRANS leads to antitumor immune memory formation. Single-cell RNA sequencing is preform to elucidate the mechanism of TRANS, which exhibits that TRANS exerts antitumor effects by optimizing the crosstalk between myeloid cells and T cells via CXCL9/10-CXCR3/DPP4. TRANS further gains better control of colorectal cancer when combined with immune checkpoints inhibitors. This study offers a novel perspective on immunotherapy by rebalancing inflammation-immunity dynamics.
- 1 August 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 62, 263-281
Open AccessChronic inflammation-responsive hydrogel restores myeloid-T cell crosstalk to reinvigorate antitumor immunity against metastatic colorectal cancer
Chronic inflammation in intermediate/advanced tumors drives burdensome protumor immune cell communication, thereby weakening immunotherapy. Conventional anti-inflammatory therapies focus on alleviating chronic inflammation whereas ignore dysfunction and scarcity of myeloid and T cells, which hinder their intercellular communication restoration. To address the dilemma, an inflammatory condition-triggered protumor inflammation-immunosurveillance shift hydrogel (TRANS) is developed to initiate adaptive immune responses mediated by intercellular communication. Triggered by inflammatory conditions, TRANS releases celecoxib (CXB) to inhibit the COX-2/PGE2 pathway, thereby reprogramming tumor-associated macrophages and mitigating protumor inflammation. Furthermore, TRANS incorporates FMS-like tyrosine kinase 3 ligands (Flt-3L) and 4-1BB agonists (α-CD137) to respectively recruit type 1 conventional DC (cDC1) and revitalize tumor-infiltrating T cells, to rejuvenate immunosurveillance. TRANS inhibits 87.50% and 88.74% of primary and secondary colorectal tumors, generates antitumor immune memory to resist tumor rechallenge, and significantly reduces lung and liver metastases. Rechallenge model shows TRANS leads to antitumor immune memory formation. Single-cell RNA sequencing is preform to elucidate the mechanism of TRANS, which exhibits that TRANS exerts antitumor effects by optimizing the crosstalk between myeloid cells and T cells via CXCL9/10-CXCR3/DPP4. TRANS further gains better control of colorectal cancer when combined with immune checkpoints inhibitors. This study offers a novel perspective on immunotherapy by rebalancing inflammation-immunity dynamics.
- Open Access
- 9 July 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
Hydrated microRNA-regulating nanoplatform for synergistic lubrication and anti-inflammation to alleviate osteoarthritis
- 9 July 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
Open AccessHydrated microRNA-regulating nanoplatform for synergistic lubrication and anti-inflammation to alleviate osteoarthritis
- Open Access
- 17 June 2026
- Published by Wiley in Advanced Functional Materials
- Vol. 36 (55) , e76550
Programmable Tumor‐Activated NanoCRISPR Platform Synergizes cGAS‐STING Activation With PD‐L1 Blockade for Potentiated Antitumor Immunity
The cGAS‐STING pathway is an essential element of antitumor immunity. However, its activation triggers immunosuppressive molecules like PD‐L1 to feedback upregulate, which limits therapeutic efficacy. Herein, we develop a programmable tumor‐activated nanoCRISPR platform (PATROL) that co‐delivers CRISPR/Cas13a‐CARM1 plasmid and PD‐L1 blocking peptide to stimulate the cGAS‐STING‐IFN‐I pathway and diminish its immunosuppressive feedback loop, thereby improving antitumor efficacy. PATROL achieves enhanced circulation longevity, tumor‐targeting specificity, and tissue penetration due to surface modifications such as PEGylation, hyaluronic acid, and TAT peptide. At the same time, its PD‐L1 blocking peptide on the surface facilitates drug accumulation with the tumor and inhibits PD‐L1 activity. Following exposure to tumor‐associated hyaluronidase, PATROL undergoes enzyme‐triggered disassembly, surface charge reversal, rapid lysosomal escape, and significant CARM1 knockdown, leading to enhanced cGAS‐STING signaling. This bifunctional approach cooperatively reprograms the immunosuppressive tumor microenvironment, increases cytotoxic T lymphocyte infiltration, and elicits powerful antitumor immunity by simultaneously blocking PD‐1/PD‐L1 signaling and activating the cGAS‐STING‐IFN‐I pathway. PATROL exhibits significant antitumor efficacy in B16‐F10 melanoma models, successfully inhibiting tumor growth and prolonging survival. As consequently, PATROL presents an innovative therapeutic strategy that achieves effective tumor suppression by enhancing antitumor immunity through dual‐pathway activation.
- 17 June 2026
- Published by Wiley in Advanced Functional Materials
- Vol. 36 (55) , e76550
Open AccessProgrammable Tumor‐Activated NanoCRISPR Platform Synergizes cGAS‐STING Activation With PD‐L1 Blockade for Potentiated Antitumor Immunity
The cGAS‐STING pathway is an essential element of antitumor immunity. However, its activation triggers immunosuppressive molecules like PD‐L1 to feedback upregulate, which limits therapeutic efficacy. Herein, we develop a programmable tumor‐activated nanoCRISPR platform (PATROL) that co‐delivers CRISPR/Cas13a‐CARM1 plasmid and PD‐L1 blocking peptide to stimulate the cGAS‐STING‐IFN‐I pathway and diminish its immunosuppressive feedback loop, thereby improving antitumor efficacy. PATROL achieves enhanced circulation longevity, tumor‐targeting specificity, and tissue penetration due to surface modifications such as PEGylation, hyaluronic acid, and TAT peptide. At the same time, its PD‐L1 blocking peptide on the surface facilitates drug accumulation with the tumor and inhibits PD‐L1 activity. Following exposure to tumor‐associated hyaluronidase, PATROL undergoes enzyme‐triggered disassembly, surface charge reversal, rapid lysosomal escape, and significant CARM1 knockdown, leading to enhanced cGAS‐STING signaling. This bifunctional approach cooperatively reprograms the immunosuppressive tumor microenvironment, increases cytotoxic T lymphocyte infiltration, and elicits powerful antitumor immunity by simultaneously blocking PD‐1/PD‐L1 signaling and activating the cGAS‐STING‐IFN‐I pathway. PATROL exhibits significant antitumor efficacy in B16‐F10 melanoma models, successfully inhibiting tumor growth and prolonging survival. As consequently, PATROL presents an innovative therapeutic strategy that achieves effective tumor suppression by enhancing antitumor immunity through dual‐pathway activation.
- 14 May 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (20) , 14443-14457
Multistage Responsive NanoCRISPR Unleashes Cascade Amplified Endogenous Apoptosis and Inhibits Epithelial-Mesenchymal Transition Simultaneously for Suppressing Tumor Growth and Metastasis
Targeting apoptotic pathways holds promise for cancer treatment; however, single-pathway approaches often struggle to overcome apoptosis resistance and metastasis. Overexpression of Inhibitor of Apoptosis Proteins (IAPs), particularly Survivin, is critically linked to these therapeutic challenges. Herein, a multistage-responsive nanoCRISPR (MIRV) system targeting the IAPs member Survivin in the nucleus and mitochondria in the cytoplasm was developed to suppress tumor growth and metastasis via cascade-amplified endogenous apoptosis and epithelial-mesenchymal transition (EMT) inhibition. By leveraging the tumor-specific targeting, enzyme-triggered penetrating and deshelling, and reactive oxygen species (ROS)-responsive capabilities, MIRV precisely delivers the Survivin-targeting CRISPR/Cas9 system and the pro-apoptotic peptide D(KLAKLAK)2 to the nucleus and cytoplasm of tumor cells, respectively. Survivin depletion-triggered endogenous apoptosis and EMT inhibition, cooperating with peptide-induced mitochondrial dysfunction, enabled MIRV to markedly suppress subcutaneous tumor growth and peritoneal metastasis with minimal side effects. Taken together, the MIRV system provides an effective strategy for the simultaneous induction of apoptosis and suppression of EMT in antitumor and antimetastatic therapies.
- 14 May 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (20) , 14443-14457
Multistage Responsive NanoCRISPR Unleashes Cascade Amplified Endogenous Apoptosis and Inhibits Epithelial-Mesenchymal Transition Simultaneously for Suppressing Tumor Growth and Metastasis
Targeting apoptotic pathways holds promise for cancer treatment; however, single-pathway approaches often struggle to overcome apoptosis resistance and metastasis. Overexpression of Inhibitor of Apoptosis Proteins (IAPs), particularly Survivin, is critically linked to these therapeutic challenges. Herein, a multistage-responsive nanoCRISPR (MIRV) system targeting the IAPs member Survivin in the nucleus and mitochondria in the cytoplasm was developed to suppress tumor growth and metastasis via cascade-amplified endogenous apoptosis and epithelial-mesenchymal transition (EMT) inhibition. By leveraging the tumor-specific targeting, enzyme-triggered penetrating and deshelling, and reactive oxygen species (ROS)-responsive capabilities, MIRV precisely delivers the Survivin-targeting CRISPR/Cas9 system and the pro-apoptotic peptide D(KLAKLAK)2 to the nucleus and cytoplasm of tumor cells, respectively. Survivin depletion-triggered endogenous apoptosis and EMT inhibition, cooperating with peptide-induced mitochondrial dysfunction, enabled MIRV to markedly suppress subcutaneous tumor growth and peritoneal metastasis with minimal side effects. Taken together, the MIRV system provides an effective strategy for the simultaneous induction of apoptosis and suppression of EMT in antitumor and antimetastatic therapies.
- 9 May 2026
- Published by Elsevier in Biomaterials
- Vol. 334, 124285
A hierarchical self-adjuvanted nanoCRISPR-based vaccine restores endogenous immune recognition and surveillance to amplify adaptive immune responses
- 9 May 2026
- Published by Elsevier in Biomaterials
- Vol. 334, 124285
A hierarchical self-adjuvanted nanoCRISPR-based vaccine restores endogenous immune recognition and surveillance to amplify adaptive immune responses
- Open Access
- 31 March 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (4) , 102718
A harmless-to-harmful switchable and spatiotemporally activated nano-CRISPR hierarchically amplifies ferroptosis in melanoma
- 31 March 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (4) , 102718
Open AccessA harmless-to-harmful switchable and spatiotemporally activated nano-CRISPR hierarchically amplifies ferroptosis in melanoma
- 2 March 2026
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 14 (7) , 1631-1651
Nanotechnology-mediated metabolic reprogramming for tumour ferroptosis: mechanisms and therapeutic prospects
Nanotechnology-mediated metabolic intervention may overcome tumour resistance by restoring ferroptosis sensitivity. This review highlights nano-based regulation of iron, lipid, amino acid, and glucose metabolism, and its antitumour potential.
- 2 March 2026
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 14 (7) , 1631-1651
Nanotechnology-mediated metabolic reprogramming for tumour ferroptosis: mechanisms and therapeutic prospects
Nanotechnology-mediated metabolic intervention may overcome tumour resistance by restoring ferroptosis sensitivity. This review highlights nano-based regulation of iron, lipid, amino acid, and glucose metabolism, and its antitumour potential.